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Abstract
Osteosarcoma is a cancer of pathological bone remodeling with high mortality and 
severe comorbidity. New therapies are urgently needed. Activin A, a member of the 
transforming growth factor β (TGFβ) superfamily, has been suggested to stimulate 
proliferation and invasion of osteosarcoma cells in vitro, thus representing a potential 
therapeutic target. In this study, inhibition of the activin receptor signaling pathway 
was explored as a therapy for osteosarcoma. In a murine intratibial osteosarcoma xen-
ograft model, two types of inhibitors were tested: (a) a soluble activin type IIA decoy 
receptor (ActRIIA-mFc), or (b) a modified variant of follistatin (FSTΔHBS-hFc), ei-
ther alone or in combination with a bisphosphonate. Both inhibitors reduced primary 
tumor development by nearly 50% compared to vehicle treatment. When ActRIIA-
mFc was combined with bisphosphonate, the effect on tumor size became even more 
pronounced (78% reduction vs. vehicle). Moreover, FSTΔHBS-hFc increased body 
weight in the face of tumor progression (14% increase vs. vehicle), and ActRIIA-mFc 
reduced the number of lung metastases when combined with bisphosphonate. The 
present study demonstrates a novel approach to treating osteosarcoma and encour-
ages further investigation of inhibition of the activin receptor signaling pathway as an 
intervention against the disease.
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1 |  INTRODUCTION
Osteosarcoma is the most common malignant primary tumor 
of bone and it has a strong propensity for metastasizing to 
the lungs. In spite of multi-agent chemotherapy, the 5-year 
survival rate remain as low as a few percentages in the elderly 
(60+ years of age) and amounts to 30% in young patients 
(0–24  years of age), when distant disease is present at the 
time of diagnosis.1
Osteosarcoma is a cancer of pathological bone remodel-
ing that includes a number of subtypes, differing in their an-
atomical location, histology, phenotype, or genetic profile.2 
Consequently, tumor heterogeneity presents a challenge in 
the discovery of new therapies. To overcome this problem, 
targeting common factors for all subtypes may serve as a 
strategy. Selective blockade of the ubiquitous transform-
ing growth factor β (TGFβ) superfamily represents such an 
option.
Activin A and growth differentiation factor 11 (GDF11) 
are members of the TGFβ superfamily that have recently 
been proposed as negative regulators of bone mass.3–5 Their 
neutralization have been reported to increase bone mass, 
bone strength, or bone formation markers in postmenopausal 
women or preclinical models of bone loss.5–8 In addition, ab-
errant activin A signaling has been shown to invoke local and 
systemic inflammation and to be a driving factor in various 
cancers.9,10
In osteosarcoma, pathological bone remodeling is thought 
to maintain a “vicious cycle” that nourishes tumor cells by re-
lease of growth factors stored within the bone matrix.11 This 
concept extends from Paget's “seed and soil” theory, origi-
nally formulated in relation to breast cancer.12 Neutralization 
of activin A and GDF11 in animal models of breast cancer 
or multiple myeloma has shown inhibition of tumor growth 
and a reduction in the number of bone metastases and os-
teolytic lesions.13,14 In relation to osteosarcoma, a single in 
vitro study found activin A enhanced proliferation and inva-
sion and migration of osteosarcoma cell lines.15 Activin A or 
GDF11 would, therefore, appear ideal targets, and yet, their 
modulation has never been attempted in in vivo models of 
osteosarcoma.
Activin A and GDF11 initiate signaling via mem-
brane proteins known as activin type II receptors (ActRIIs; 
ActRIIA and ActRIIB). Collectively, compounds that prevent 
transduction through these receptors may be referred to as in-
hibitors of the activin receptor signaling pathway (IASPs).6,16
Bisphosphonates are chemically stable derivatives of in-
organic pyrophosphate that have a natural predilection for 
hydroxyapatite crystals.17 During bone remodeling, bisphos-
phonate is absorbed by the osteoclast and incorporated into 
the cell's adenosine triphosphate production.18 This sabo-
tage of the energy pool is cytotoxic and ultimately leads to 
the death of the osteoclast. Because of the antiresorptive 
capability bisphosphonate is a common therapeutic agent in 
disease with osteoclast mediated bone loss, including some 
forms of metastatic malignancy.19 Studies of osteosarcoma 
cell lines suggest bisphosphonate is also toxic to the osteo-
sarcoma cell type, and in murine models of osteosarcoma 
bisphosphonate improves survival and reduces the number 
of bone lesions.20–22
In this study, we explored inhibition of the activin recep-
tor signaling pathway as a therapy for osteosarcoma. Two 
types of IASPs were tested: 1) a soluble activin type IIA 
decoy receptor (ActRIIA-mFc),4 and 2) a modified variant 
of the native antagonist, follistatin (FST), (FSTΔHBS-hFc).
16 
The two IASPs were tested alone or in combination with bis-
phosphonate in an intratibial human xenograft osteosarcoma 
mouse model. The purpose of including bisphosphonate was 
to investigate the combination of an established antiresorp-
tive with an inhibitor of growth factors that are likely released 
by the destruction of bone matrix as is suggested by the “seed 
and soil” theory.
Both IASPs were found to reduce tumor development and 
tumor-associated bone remodeling with the greatest effect 
observed in combination with bisphosphonate. Inhibition 
of the activin receptor signaling pathway represents a novel 
therapeutic strategy against osteosarcoma.
2 |  MATERIALS AND METHODS
2.1 | Construction and expression and 
purification of ActRIIA-mFc and FSTΔHBS-hFc
The construction and expression and purification procedures 
of ActRIIA-mFc and FSTΔHBS-hFc were recently described 
in detail.16 Briefly, ActRIIA-mFc represents a fusion protein 
of the human ActRIIA ectodomain fused to the Fc region of 
murine IgG2a, including a TGGG linker.
The FST analog, FSTΔHBS-hFc, was generated by replac-
ing the heparin-binding sequence (HBS) of native FST315 by 
a structurally related sequence, so as to reduce its heparan 
sulfate binding capacity and thus increase half-life.23 Finally, 
the protein was fused to the Fc of human IgG1.
The vehicle for both recombinant proteins was a buffer 
containing 50  mmol/L KPO4, 165  mmol/L sucrose, 0.01% 
Tween 20, adjusted to a pH of 7.4.
2.2 | In vitro validation of therapeutics
The ability of ActRIIA-mFc or FSTΔHBS-mFc to prevent in-
duction of Smad 2/3 signaling was quantified and compared 
to native FST315 in a bioassay of HEK293 cells containing 
a (CAGA)12-luciferase sequence (a readout for Smad 2/3 
signaling) as previously described.16,24 Briefly, cells were 
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stimulated with activin A and co-treated with a concentra-
tion range of native FST315, FSTΔHBS-mFc, or ActRIIA-
mFc. For the neutralization bioassay, the murine ortholog of 
FSTΔHBS-Fc was used. Cells were lysed after 24 h and the 
luciferase signal was quantified. A dose-response curve was 
plotted and the half-maximal inhibitory concentration (IC50) 
calculated. The bioassay was performed four times using 
four different batches of recombinant protein.
The ability of ActRIIA-Fc or FSTΔHBS-hFc to inhibit 
activin A-stimulated osteoclast formation was quantified 
in an assay utilizing peripheral blood mononuclear cells 
(PBMC) obtained from whole blood of healthy individ-
uals and sorted for CD14 positive PBMCs with a human 
CD14 Selection Kit (#18058, STEMCELL Technologies). 
The manufacturers' instruction was followed and the 
Manual EasySep protocol with the Purple EasySep Magnet 
(#18000, STEMCELL Technologies) was used. Cells were 
cultured in MEM Alpha Medium supplemented with 15% 
heat inactivated fetal bovine serum. CD14 positive cells 
(60.000 cells per/well in a 96 wells plate) were differen-
tiated in the presence of macrophage-colony stimulating 
factor (m-CSF, 25 ng/ml) and receptor activator of NFκβ 
ligand (RANKL, 60  ng/ml) as described by Susa et al.25 
From day four, activin A (0.5  nmol/L), native FST315 
(100  nmol/L), FSTΔHBS-hFc (100  nmol/L), ActRIIA-mFc 
(100  nmol/L), or the bisphosphonate, ZOL (0.5  µmol/L), 
were added to the tissue culture medium.
Following fixation, tartrate resistant acid phosphatase 
(TRAP) histochemistry was performed. Cells were incubated 
with 0.2 M acetate buffer for 20 min at room temperature, 
then, incubated with 0.5 mg/ml Naphthol AS-MX phosphate 
(#855, Sigma-Aldrich) and 1.1  mg/mL Fast Red TR Salt 
(#F8764, Sigma-Aldrich) in the presence of 50 mmol/L so-
dium tartrate for 1 h at 37°C, and then, washed with PBS and 
stained with Hoechst (#H3570, Life Technologies, 1:10.000, 
10 min, room temperature). Osteoclast studies were per-
formed two times and in triplicate. Wells were photographed 
in quadruplicate and the number of TRAP positive, large 
multinucleated osteoclasts (approximately 100–200 µm) was 
determined after 14 days of culture using ImageJ (http://rsb.
info.nih.gov/ij/).
2.3 | Animals and osteosarcoma model
Human 143B cells (RRID: CVCL_2270) were obtained 
from the American Type Culture Collection (ATCC CRL-
8303). Cells were cultured in DMEM (4.5  g/L glucose)/
HamF12 (1:1) tissue culture medium (Invitrogen), sup-
plemented with 10% heat-inactivated FCS (GIBCO), at 
37°C in a humidified atmosphere (5% CO2). 143B cells 
were transduced with lacZ and mCherry gene constructs 
as previously described,26 resulting in the 143B/lacZ/
mCherry cell line. Cells were authenticated by multiplex 
PCR (Microsynth) using the PowerPlex®16HS system 
(Promega) and verified by comparison with the database 
at the Collection of Microorganisms and Cell Cultures 
(DSMZ). Absence of mycoplasma was confirmed by PCR 
(results not shown).
The present study employed an intratibial human xeno-
graft osteosarcoma mouse model together with 4 weeks of 
intervention therapy. Severe combined immunodeficient 
(SCID) mice, CB17/lcr-Prkdcscidd/lcrlcoCrl, were obtained 
from Charles River Laboratories and kept for a 10-day ac-
climatization period before orthotopic tumor cell injection. 
Orthotopic tumor cell delivery was via left intratibial injec-
tion with 105 143B/lacZ/mCherry cells as previously de-
scribed.27 Following tumor growth, mice were treated with 
buprenorphine in accordance with current specifications 
from the local veterinary office.
2.4 | In vivo imaging system
In vivo fluorescence imaging was performed for the visu-
alization of mCherry expressing 143B cells within intratibial 
primary tumors. Tumor viability was assessed 1 week after 
tumor cell injection and thereafter regularly throughout the 
study using the IVIS Lumina XR (PerkinElmer) under gas 
anesthesia (2–5% isoflurane/O2). Epi-fluorescence and spec-
tral unmixing (excitation 605 nm, emission collected at 660, 
680, and 700  nm) was analyzed using Living Image v 4.4 
software (PerkinElmer) and presented as average radiant ef-
ficiency [(p/s/cm2/sr)/(µW/cm2].
2.5 | Monotherapy against osteosarcoma
Forty-eight 11-week-old female SCID mice were rand-
omized into three groups according to weight: vehicle (KPO4, 
n = 12), ActRIIA-mFc (n = 12), and FSTΔHBS-hFc (n = 12). 
A fourth group, receiving standard antiresorptive therapy, 
bisphosphonate (ZOL, n = 12), was included for compari-
son. Treatment began 11 days after tumor cell injection. Both 
ActRIIA-mFc (10 mg/kg) and FSTΔHBS-hFc (10 mg/kg) were 
administered intraperitoneally, twice weekly. ZOL (100 µg/
kg) was administered subcutaneously, twice weekly. During 
the experiment, three mice died prematurely, one in each of 
the active treatment groups; two mice were found dead in 
their cage, one mouse died during blood sampling.
Mice were weighed weekly and at sacrifice, 34 days after 
tumor cell injection. Tumor growth was monitored by caliper 
measurements and the Faxitron MX-20 cabinet X-ray system 
(Faxitron X-ray LLC) as described.27 Lungs were perfused 
in situ and following excision micro and macro lung surface 
metastases were counted as described.28 The tibia and tumor 
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tissue were dissected and stored in 4% of paraformaldehyde/
PBS until analysis.
2.6 | Combination therapy against 
osteosarcoma
Seventy-two 11-week-old female SCID mice were rand-
omized into six groups according to weight: vehicle (KPO4, 
n = 13), ActRIIA-mFc (n = 11), FSTΔHBS-hFc (n = 12), ZOL 
(n = 12), ActRIIA-mFc +ZOL (n = 12), and FSTΔHBS-hFc 
+ZOL (n = 12). Three mice, two from the vehicle and one 
from the FSTΔHBS-hFc group, were excluded because they 
did not develop a tumor, based on the absence of mCherry 
signal and lacZ staining following sacrifice. Two mice died 
during the in vivo µCT scan (procedure see below) due to 
respiratory insufficiency not related to treatment, one in the 
ActRIIA-mFc and one in the ZOL group. Treatment began 
11 days after tumor cell injection. The same dosage and injec-
tion protocol were applied as in the monotherapy experiment.
2.7 | In vivo microcomputed 
tomography analysis
Animals were anesthetized (2–5% isoflurane/O2) and placed 
in the supine position while hind limbs were scanned with an 
isotropic resolution of 17 µm in a Bruker/SkyScan-1176 in 
vivo X-ray µCT (Bruker). Adhering to current guidelines,29 
the following settings were used: X-ray voltage 50 kV, tube 
current 500 µA, exposure 290 ms, frame averaging 2, with 
a rotation step of 0.8 degrees over a 198 degree trajectory 
(“180-degree” setting), creating 247 raw image files per scan. 
Three-dimensional datasets were generated using Cone-
Beam reconstruction software (NRecon v 1.6.9.18, Bruker).
Increasing soft tissue as a result of tumor expansion 
confounds the bone volume fraction (defined as bone vol-
ume (BV)/tissue volume), and thus, total BV was chosen 
as the primary µCT outcome. A region of interest of the 
tibia was manually drawn (CtAnalyser v 1.13.11.0, Bruker) 
starting from the tibial plateau down to the distal junction 
with the fibula. After global segmentation, BV was calcu-
lated at the start of the experiment, prior to treatment, and 
at the study end. No differences were observed between 
groups at the starting point.
2.8 | Alkaline phosphatase activity
An alkaline phosphatase assay was performed using a fluo-
rometric Alkaline Phosphatase Assay Kit (ab83371, Abcam) 
following the manufacturer's instructions. Fluorescence (excita-
tion 360 nm, emission 440 nm) was measured in a Spectramax 
Gemini XS plate reader (Molecular devices). Alkaline phos-
phatase activity was calculated as the amount of 4-methyl-
umbelliferone (4-MU) generated over the reaction time and 
normalized to the total protein concentration in tissue lysates.
2.9 | Assessment of tumor necrosis
Upon sacrifice, the hind limb tumor was cut in half along 
the longitudinal axis, fixed in 4% buffered paraformaldehyde 
for 2 days and then decalcified for 2 weeks using Osteosoft 
(#101728, Merck Millipore). After routine paraffin embed-
ding, sections (3–5 µm thick) were stained with hematoxylin 
and eosin. The amount of tumor necrosis was scored by a 
veterinary pathologist in a blinded manner and as follows: 
grade 0, no necrosis; grade 1, necrosis below 20% of the total 
tumor surface; grade 2, necrosis greater than 20% but less 
than 40%; grade 3: necrosis greater than 40% but less than 
60%; grade 4: necrosis greater than 60% but less than 80%; 
grade 5, necrosis greater than 80%.
2.10 | Statistical analysis
All results are presented as mean  ±  SEM. Normally 
distributed data were analyzed using either a one-way 
ANOVA including all groups or a two-way ANOVA when 
comparing two categorical independent, repeatedly meas-
ured variables. Multiple comparisons were corrected using 
Bonferroni's test. For data with a non-Gaussian distribu-
tion, Kruskal–Wallis followed by Dunn's test for multiple 
comparisons was used.
In the monotherapy experiment, all therapies were com-
pared with the vehicle group as control and with each other.
In the combination therapy experiment, all therapies were 
compared with the vehicle group as control and the monother-
apies with each other. Furthermore, ZOL monotherapy was 
compared to the combination therapies, that is, ZOL versus 
ActRIIA-mFc + ZOL or ZOL versus FSTΔHBS-hFc + ZOL, 
and finally both combination therapies were compared with 
each other.
Differences were regarded as statistically significant when 
p < 0.05, and any difference described between groups is im-
plied statistically significant unless otherwise stated.
3 |  RESULTS
3.1 | In vitro validation of therapeutics
The ligand neutralizing activity of ActRIIA-mFc or 
FSTΔHBS-mFc was compared to native FST315 using an in 
vitro bioassay. Both ActRIIA-mFc and FSTΔHBS-mFc were 
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capable of neutralizing activin A with IC50's in the same 
picomolar range as native FST315 (Figure 1A). In addition, 
the molecules were tested for their ability to block activin 
A's enhancement of differentiation of human CD14-positive 
PBMCs toward multinucleated TRAP positive osteoclasts. 
The bisphosphonate, ZOL, was included as a control. In the 
presence of m-CSF and RANKL, the stimulatory effect of ac-
tivin A on osteoclastogenesis was abolished by the presence 
of native FST315, ActRIIA-mFc, FSTΔHBS-mFc, or ZOL alike 
after 14 days of culture (Figure 1B, C).
3.2 | Inhibition of the activin receptor 
signaling pathway in an orthotopic 
osteosarcoma mouse model
The therapeutic potential of ActRIIA-mFc or FSTΔHBS-hFc 
therapy was investigated in a metastatic, orthotopic xeno-
graft osteosarcoma mouse model. Highly metastatic human 
143B/lacZ/mCherry cells were injected into the left tibia of 
SCID mice. After 5 weeks, vehicle-treated mice all had mac-
roscopically visible bone erosions and pulmonary metastatic 
spread similar to the examples shown in Figure 2A. During 
week 0, IVIS imaging was used to verify a viable tumor in all 
mice (Figure 2B). Intervention therapy was initiated 11 days 
after tumor cell injection and is referred to as week 1.
3.3 | FSTΔHBS-hFc therapy counters weight 
loss and both ActRIIA-mFc and FSTΔHBS-hFc 
reduce osteosarcoma tumor growth
Intervention therapies were administered to the mice twice 
weekly for 4 weeks. Vehicle, ActRIIA-mFc (10 mg/kg), 
and FSTΔHBS-hFc (10 mg/kg) were delivered intraperito-
neally, while ZOL (100 µg/kg) was delivered subcutane-
ously. Serum levels of ActRIIA-mFc and FSTΔHBS-hFc 
were measured regularly and demonstrated a high cir-
culating level of each molecule in the bloodstream 
(Figure 3A).
Following tumor cell injection, mice treated with vehicle, 
ActRIIA-mFc, or ZOL gradually developed cachexia (Figure 
3B). In contrast, mice treated with FSTΔHBS-hFc increased 
their body weight regardless of tumor progression until the 
period between week 3 and 4, where the mice succumbed 
to the tumor burden. Notwithstanding this final decline, 
FSTΔHBS-hFc treated mice were 14% heavier than vehicle 
mice at the study end.
Tumor volume development was mitigated by all three 
treatments with nearly a halving of the tumor volume at 
the study end compared to vehicle treatment (Figure 3C). 
A tendency for a reduction in the number of lung mi-
crometastases was observed with FSTΔHBS-hFc therapy, 
but neither micro- nor macrometastases were significantly 
F I G U R E  1  In vitro validation of therapeutics. (A) Ligand neutralization by native FST315, FSTΔHBS-mFc, or ActRIIA-mFc. A luciferase 
reporter cell line under control of a Smad2/3 sensitive promoter was stimulated with activin A in the presence of different concentrations of native 
FST315, FSTΔHBS-mFc, or ActRIIA-mFc. Luc, luciferase. (B) CD14-positive PBMCs were differentiated into TRAP-positive huge (approximately 
100–200 µm), multinucleated osteoclasts in the presence of m-CSF, RANKL, activin A, and either FST315, FSTΔHBS-hFc, ActRIIA-mFc, or ZOL. 
Osteoclasts were counted after 14 days of culture. (C) Representative images of TRAP-positive, multinucleated osteoclasts (arrows) with indicated 
treatment. One-way analysis of variance with Bonferroni's correction of multiple comparisons was employed for statistical analysis of the osteoclast 
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affected by ActRIIA-mFc or FSTΔHBS-hFc therapy (Figure 
3D, E). The lungs of ZOL treated mice showed less lung 
micrometastases.
3.4 | Combination therapy with ActRIIA-
mFc and ZOL provide the greatest reduction in 
osteosarcoma tumor volume
A second in vivo study was conducted to see if additional 
benefit could be gained by combining ActRIIA-mFc or 
FSTΔHBS-hFc with ZOL.
From week 2 and throughout the study, FSTΔHBS-hFc treated 
mice were heavier than vehicle-treated mice (Figure 4A). Neither 
ActRIIA-mFc, nor ZOL therapy, nor their combination led to in-
creased body mass at sacrifice, after 4 weeks of treatment.
The capability of ActRIIA-mFc, FSTΔHBS-hFc, or ZOL 
to reduce primary tumor development was confirmed (Figure 
4B). Tumor volume was further reduced when ActRIIA-mFc 
was combined with ZOL (78% reduction vs. vehicle), while 
FSTΔHBS-hFc in combination with ZOL did not significantly 
alter tumor volume compared to ZOL therapy alone (Figure 4B).
The combination of ActRIIA-mFc and ZOL caused a signifi-
cant reduction in micro- but not macrometastases (Figure 4C, D).
In summary, ActRIIA-mFc and FSTΔHBS-hFc and ZOL 
were all found to reduce osteosarcoma tumor volume in two 
independent experiments. FSTΔHBS-hFc countered weight loss, 
especially in combination with ZOL, and ZOL alone or in com-
bination with ActRIIA-mFc reduced lung micrometastases.
3.5 | Both ActRIIA-mFc and FSTΔHBS-hFc 
mitigate bone destruction
We examined the tumor bearing hind limbs in both stud-
ies using in vivo µCT. Although tumor-related osteoid for-
mation does occur in the tibia, intramedullary injection 
of 143B osteosarcoma cells in SCID mice mainly results 
F I G U R E  2  The in vivo intratibial xenograft model of osteosarcoma. (A) Left panel, X-ray image of the intratibial inoculation of metastatic 
143B/lacZ/mCherry cells into SCID mice at T = 0 week. Middle panel, a representative X-ray image of visible bone erosions from a specimen 
in the vehicle-treated group at the study end, T = 4 weeks. Right panel, a representative example of lacZ-positive pleural metastases (white 
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in an osteolytic phenotype. The presence of osteolytic le-
sions was most prominent in the vehicle-treated group 
(Figure 5A).
µCT analysis of the tibiae demonstrated ActRIIA-mFc as 
well as FSTΔHBS-hFc mitigated the pathological destruction 
of bone (Figure 5B). This was observable in the combina-
tion therapy experiment too, albeit the finding did not reach 
significance for FSTΔHBS-hFc (Figure 5C). ZOL therapy 
increased bone mass without any apparent benefit of being 
combined with ActRIIA-mFc or FSTΔHBS-hFc (Figure 5C).
Microscopically, localized or multifocal new bone forma-
tion was found at the periosteal and to a lesser extent at the 
endocortical surface in all compound treated groups (Figure 
5D). To confirm the anabolic activity in the tumor bone mi-
croenvironment, alkaline phosphatase activity was determined 
in tissue extracts of tumor bearing hind limbs. Alkaline phos-
phatase is an important indicator of bone mineralization and 
a prominent increase was observed when ActRIIA-mFc or 
FSTΔHBS-hFc was used in combination with ZOL (Figure 5E).
An investigation conducted by a veterinary pathologist 
(GP) concluded that the primary tumor consisted of large 
areas of bone and soft tissue effacement associated with in-
filtrating neoplastic osteosarcoma cells. These cells exhibited 
mitotic figures, prominent anisocytosis, cellular atypia, and a 
variable amount of necrosis represented by either multifocal 
small groups of necrotic neoplastic cells, or more discrete, 
confluent areas of necrosis infiltrated by neutrophils. Only 
therapies including ZOL were characterized by a higher ne-
crosis score within the primary tumor compared to the vehi-
cle group, indicating a cytotoxic effect of ZOL (Figure 5F).
Taken together, these results demonstrate that ActRIIA-
mFc and FSTΔHBS-hFc both mitigated osteosarcoma-induced 
pathological bone remodeling, albeit to a lesser extent than 
ZOL (100 µg/kg) with the applied dosage regimen of 10 mg/
kg, twice weekly. The prominent alkaline phosphatase activity 
upon add-on of ZOL to either ActRIIA-mFc or FSTΔHBS-hFc 
points toward an increased bone anabolic drive on top of the 
osteoclastic inhibition and cytotoxicity of ZOL therapy alone.
4 |  DISCUSSION
Osteosarcoma is a deadly cancer associated with extended 
tumor-associated pathological bone remodeling. There is an 
unmet need for therapies that effectively reduce mortality 
and comorbidity.
In the present study, we explored the use of two dif-
ferent IASPs, a soluble activin type IIA decoy receptor 
and a follistatin analog, as therapeutics against osteosar-
coma in an in vivo intratibial xenograft model.27 Two ex-
periments were conducted: An exploratory monotherapy 
F I G U R E  3  Inhibition of the activin receptor signaling 
pathway as monotherapy against osteosarcoma. Measurement of 
ActRIIA-mFc or FSTΔHBS-hFc in serum 24 h after a single-dose 
intravenous injection (A), absolute body weight (B), tumor volume 
(C), lung micrometastases (D), and lung macrometastases (E) in 
a monotherapy experiment of IASPs or bisphosphonate in SCID 
mice. Two-way analysis of variance with Bonferroni's correction of 
multiple comparisons was employed for statistical analysis of body 
weight and tumor volume. Kruskal–Wallis followed by Dunn's 
multiple comparison was employed for micrometastases. One-way 
analysis of variance with Bonferroni's multiple comparison was 
employed for macrometastases. Data presented as means ± SEM. 
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study and a second experiment investigating the use of 
combination therapy with the established antiresorptive, 
bisphosphonate. Both IASPs were found capable of reduc-
ing tumor growth and tumor-associated bone remodeling. 
Furthermore, ActRIIA-mFc reduced lung metastatic ten-
dency when combined with bisphosphonate and FSTΔHBS-
hFc counteracted cachexia.
Previously, ActRIIA-Fc therapy in murine models of multi-
ple myeloma or metastatic breast cancer has shown inhibition 
of tumor growth and a reduction in the number of metasta-
ses and osteolytic lesions.13,14 The data presented here extend 
these findings and show that ActRIIA-mFc or FSTΔHBS-hFc 
therapy may also blunt osteosarcoma primary tumor volume, 
possibly as a consequence of modulated tumor-associated 
bone remodeling: Both ActRIIA-mFc and FSTΔHBS-hFc were 
capable of abolishing activin A's enhancement of osteoclas-
togenesis. In turn, this could lead to a reduction in the release 
of growth factors, thus, breaking the “seed and soil” cycle by 
denying implantation or growth of tumor cells.
In relation to chemotherapy, the reduction in primary 
tumor volume produced by the combination of a bisphospho-
nate and ActRIIA-mFc was roughly equivalent to high-dose, 
intra-arterial Cisplatin therapy in a study employing the same 
model of osteosarcoma.30 Still, it should be emphasized that 
these are two separately performed studies and therefore not 
directly comparable.
In many bone-associated cancers, bisphosphonates such as 
zoledronic acid are considered standard of care therapy against 
skeletal-related events and preclinical studies have reported its 
benefit in treatment of osteosarcoma too.20,21 Bisphosphonates 
are believed to be directly cytotoxic to a number of tumor cell 
types,31 which is consistent with our finding of an increased 
tumor necrosis score in the bisphosphonate-treated groups. In 
contrast, neither ActRIIA-mFc nor FSTΔHBS-hFc had direct 
cytotoxic effects. However, the use of bisphosphonate in osteo-
sarcoma treatment has not been implemented despite its pro-
posed antitumor effect. This is because clinical trials have yet 
to demonstrate its merit against osteosarcoma, representing a 
discrepancy between preclinical and clinical results.32
We were surprised to find that alkaline phosphatase ac-
tivity was enhanced in tumor extracts when either IASP was 
combined with bisphosphonate. The clinical implication of 
this is difficult to gauge, but the phenomenon warrants fur-
ther investigation, especially since the observed effect was 
virtually additive.
A third TGFβ superfamily member, myostatin, also sig-
nals through activin type II receptors and is also neutralized 
by IASPs (most effectively by FST). In mammals, myostatin 
is renowned as a negative regulator of skeletal muscle mass, 
although in primates it appears to share this feature with ac-
tivin A.33 Body weight and muscle mass deterioration often 
follow in the wake of cancer and there is a vacuum of therapies 
F I G U R E  4  Inhibition of the activin receptor signaling pathway in combination with bisphosphonate therapy against osteosarcoma. Absolute 
body weight (A), tumor volume (B), lung micrometastases (C), and lung macrometastases (D) in a combination therapy experiment of IASPs and 
bisphosphonate in SCID mice. Two-way analysis of variance with Bonferroni's correction of multiple comparisons was employed for statistical 
analysis of body weight and tumor volume. Kruskal-Wallis followed by Dunn's multiple comparison was employed for micrometastases. One-way 
analysis of variance with Bonferroni's multiple comparison was employed for macrometastases. Data presented as means ± SEM. *p < 0.05 versus 
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against this condition known as cachexia.34–38 Cachexia leads 
to a reduction in performance status and quality of life and 
signifies the terminal period of the patient.39 The ability of 
FSTΔHBS-hFc to increase body weight in the face of progress-
ing osteosarcoma is, therefore, an interesting feature and it is 
likely attributable to skeletal muscle preservation as has been 
noted in other cancer types with some IASPs.40,41 ActRIIA-
mFc did not significantly alter body weight and this difference 
between the IASPs may likely be attributed to ActRIIA-mFc 
not blocking myostatin as strongly as FSTΔHBS-hFc.
16
F I G U R E  5  Inhibitors of the activin receptor signaling pathway and bisphosphonate mitigate tumor-associated bone remodeling. 
Representative µCT images of tumor bearing hind limbs (A), bone volume of inoculated tibiae in the monotherapy experiment (B), bone volume 
of inoculated tibiae in the combination therapy experiment (C). In both experiments, the bone loss in the vehicle group between week 0 and 4 was 
significant, symbols omitted for clarity. Hematoxylin and eosin stained sections indicating periosteal (black arrowhead) and endocortical bone 
formation (white arrowhead; BM, bone marrow cavity; (D), alkaline phosphatase activity shown as 4-MU generation per mg of protein in tumor 
tissue extracts (E), and tumor necrosis score (F). Two-way analysis of variance with Bonferroni's correction of multiple comparisons was employed 
for statistical analysis of in vivo μCT data. Kruskal–Wallis followed by Dunn's multiple comparison was employed for the alkaline phosphatase 
activity. One-way analysis of variance with Bonferroni's multiple comparison was employed for the tumor necrosis score. Data presented as 
means ± SEM. *p < 0.05 versus vehicle, #p < 0.05 versus ActRIIA-mFc, †p < 0.05 versus ZOL, ‡p < 0.05 versus ZOL + ActRIIA-mFc.
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In conclusion, ActRIIA-mFc and FSTΔHBS-hFc therapy 
both showed a potential for reducing primary tumor volume 
and tumor-associated bone remodeling alone or in combina-
tion with bisphosphonate. Moreover, FSTΔHBS-hFc was found 
to counter cachexia and ActRIIA-mFc reduced the number of 
lung metastases when combined with bisphosphonate. This 
is the first study demonstrating that in vivo inhibition of the 
activin receptor signaling pathway may be utilized as an in-
tervention against osteosarcoma.
Within the last year, the first IASP, an ActRIIB based 
molecule, has received FDA approval for use in transfusion 
dependent beta thalassemia or lower-risk myelodysplastic 
syndromes. Moreover, an ActRIIA-based molecule has re-
ceived FDA breakthrough therapy designation for pulmonary 
arterial hypertension and is currently being investigated in 
phase 2 (NCT03738150). The findings of the present study 
encourage further investigation of this drug class in osteosar-
coma treatment too.
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